164 related articles for article (PubMed ID: 23672077)
1. [Clinical significance of the measurement of serum cytokeratin-18 in patients with non-alcoholic steatohepatitis].
Watanabe T; Takemura M; Saito K; Ito H; Hattori T; Sekine A; Yamada K; Kato T; Tomita E; Matsuoka T; Seishima M
Rinsho Byori; 2013 Jan; 61(1):19-24. PubMed ID: 23672077
[TBL] [Abstract][Full Text] [Related]
2. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers.
Shen J; Chan HL; Wong GL; Choi PC; Chan AW; Chan HY; Chim AM; Yeung DK; Chan FK; Woo J; Yu J; Chu WC; Wong VW
J Hepatol; 2012 Jun; 56(6):1363-70. PubMed ID: 22314419
[TBL] [Abstract][Full Text] [Related]
3. Apoptotic and anti-apoptotic seromarkers for assessment of disease severity of non-alcoholic steatohepatitis.
El Bassat H; Ziada DH; Hasby EA; Nagy H; Abo Ryia MH
Arab J Gastroenterol; 2014 Mar; 15(1):6-11. PubMed ID: 24630506
[TBL] [Abstract][Full Text] [Related]
4. Serum intercellular adhesion molecule-1 in patients with nonalcoholic steatohepatitis: comparison with alcoholic hepatitis.
Ito S; Yukawa T; Uetake S; Yamauchi M
Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S83-7. PubMed ID: 17331172
[TBL] [Abstract][Full Text] [Related]
5. Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers.
Shen J; Chan HL; Wong GL; Chan AW; Choi PC; Chan HY; Chim AM; Yeung DK; Yu J; Chu WC; Wong VW
Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1057-66. PubMed ID: 23066946
[TBL] [Abstract][Full Text] [Related]
6. Adipohormones as prognostric markers in patients with nonalcoholic steatohepatitis (NASH).
Krawczyk K; Szczesniak P; Kumor A; Jasinska A; Omulecka A; Pietruczuk M; Orszulak-Michalak D; Sporny S; Malecka-Panas E
J Physiol Pharmacol; 2009 Oct; 60 Suppl 3():71-5. PubMed ID: 19996485
[TBL] [Abstract][Full Text] [Related]
7. Characteristics and diagnosis of NAFLD/NASH.
Hashimoto E; Taniai M; Tokushige K
J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():64-70. PubMed ID: 24251707
[TBL] [Abstract][Full Text] [Related]
8. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years.
Wong VW; Wong GL; Choi PC; Chan AW; Li MK; Chan HY; Chim AM; Yu J; Sung JJ; Chan HL
Gut; 2010 Jul; 59(7):969-74. PubMed ID: 20581244
[TBL] [Abstract][Full Text] [Related]
9. Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children.
Feldstein AE; Alkhouri N; De Vito R; Alisi A; Lopez R; Nobili V
Am J Gastroenterol; 2013 Sep; 108(9):1526-31. PubMed ID: 23752877
[TBL] [Abstract][Full Text] [Related]
10. The association between adipocytokines and biomarkers for nonalcoholic fatty liver disease-induced liver injury: a study in the general population.
Zelber-Sagi S; Ratziu V; Zvibel I; Goldiner I; Blendis L; Morali G; Halpern Z; Oren R
Eur J Gastroenterol Hepatol; 2012 Mar; 24(3):262-9. PubMed ID: 22246329
[TBL] [Abstract][Full Text] [Related]
11. Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels.
Tsutsui M; Tanaka N; Kawakubo M; Sheena Y; Horiuchi A; Komatsu M; Nagaya T; Joshita S; Umemura T; Ichijo T; Matsumoto A; Yoshizawa K; Aoyama T; Tanaka E; Sano K
J Clin Gastroenterol; 2010 Jul; 44(6):440-7. PubMed ID: 20104187
[TBL] [Abstract][Full Text] [Related]
12. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
[TBL] [Abstract][Full Text] [Related]
13. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease.
Lemoine M; Ratziu V; Kim M; Maachi M; Wendum D; Paye F; Bastard JP; Poupon R; Housset C; Capeau J; Serfaty L
Liver Int; 2009 Oct; 29(9):1431-8. PubMed ID: 19422483
[TBL] [Abstract][Full Text] [Related]
14. A novel pathophysiological-based panel of biomarkers for the diagnosis of nonalcoholic steatohepatitis.
Grigorescu M; Crisan D; Radu C; Grigorescu MD; Sparchez Z; Serban A
J Physiol Pharmacol; 2012 Aug; 63(4):347-53. PubMed ID: 23070083
[TBL] [Abstract][Full Text] [Related]
15. Non-invasive diagnosis of nonalcoholic fatty liver and nonalcoholic steatohepatitis.
Adams LA; Feldstein AE
J Dig Dis; 2011 Feb; 12(1):10-6. PubMed ID: 21091933
[TBL] [Abstract][Full Text] [Related]
16. Noninvasive clinical model for the diagnosis of nonalcoholic steatohepatitis in overweight and morbidly obese patients undergoing bariatric surgery.
Pirvulescu I; Gheorghe L; Csiki I; Becheanu G; Dumbravă M; Fica S; Martin S; Sarbu A; Gheorghe C; Diculescu M; Copăescu C
Chirurgia (Bucur); 2012; 107(6):772-9. PubMed ID: 23294957
[TBL] [Abstract][Full Text] [Related]
17. [Clinical and histological features of non-alcoholic fatty liver disease].
Shi JP; Xun YH; Hu CB; Zhang L; Liu H; Lou GQ; Fan JG
Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):812-6. PubMed ID: 19958638
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis.
Shimada M; Kawahara H; Ozaki K; Fukura M; Yano H; Tsuchishima M; Tsutsumi M; Takase S
Am J Gastroenterol; 2007 Sep; 102(9):1931-8. PubMed ID: 17511754
[TBL] [Abstract][Full Text] [Related]
19. Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis.
Joka D; Wahl K; Moeller S; Schlue J; Vaske B; Bahr MJ; Manns MP; Schulze-Osthoff K; Bantel H
Hepatology; 2012 Feb; 55(2):455-64. PubMed ID: 21993925
[TBL] [Abstract][Full Text] [Related]
20. Cytokeratin 18, alanine aminotransferase, platelets and triglycerides predict the presence of nonalcoholic steatohepatitis.
Cao W; Zhao C; Shen C; Wang Y
PLoS One; 2013; 8(12):e82092. PubMed ID: 24324749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
